VisionSA \u62db\u52df\u4e86\u7b2c\u4e00\u4f4d\u968f\u673a\u60a3\u8005\u540e<\/a>\uff0c\u4fbf\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u3002<\/p>\n\u5176\u4ed6\u8bd5\u9a8c\u7ad9\u70b9\u5df2\u5f00\u59cb\u5728\u6fb3\u5927\u5229\u4e9a\u548c\u82f1\u56fd\u79ef\u6781\u62db\u52df\uff0c\u5168\u7403\u603b\u5171\u5c06\u5f00\u8bbe40\u4e2a\u7ad9\u70b9\u200b\u200b\u3002<\/p>\n
\u603b\u4e4b\uff0cIIH Evolve III \u671f\u8bd5\u9a8c\u5c06\u5bf9\u5927\u7ea6 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\u8fdb\u884c\u8bd5\u9a8c\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\uff0c\u4e3a\u671f 24 \u5468\uff0c\u6bcf\u5468\u4e00\u6b21\u3002<\/p>\n
\u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u89c2\u5bdf\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u57fa\u7ebf\u7684\u53d8\u5316\uff0c\u6b21\u8981\u7ec8\u70b9\u4e0e\u89c6\u529b\u548c\u5934\u75db\u7ed3\u679c\u6709\u5173\u3002<\/p>\n
\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b<\/h2>\n
IIH \u662f\u7531\u201c\u4e25\u91cd\u5347\u9ad8\u201d\u7684\u9885\u5185\u538b\u5f15\u8d77\u7684\uff0c\u53ef\u5f15\u53d1\u81f4\u6b8b\u6027\u5934\u75db\u5e76\u538b\u8feb\u89c6\u795e\u7ecf\u3002<\/p>\n
\u6709\u6761\u4ef6\u7684\u5728\u80a5\u80d6\u5973\u6027\u4e2d\u6700\u4e3a\u666e\u904d\uff0c\u53d1\u75c5\u901a\u5e38\u4e3a 20-30 \u5c81\u3002<\/p>\n
\u5b83\u662f\u4e00\u79cd\u53d1\u5c55\u8fc5\u901f\u7684\u75be\u75c5\uff0c\u53d1\u75c5\u7387\u5728\u8fc7\u53bb\u5341\u5e74\u4e2d\u589e\u52a0\u4e86 350%\u3002<\/p>\n
Invex \u7684 IIH Evolve III \u671f\u8bd5\u9a8c\u65e8\u5728\u6ee1\u8db3\u6b27\u76df\u3001\u82f1\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u6279\u51c6\u7528\u4e8e\u6cbb\u7597 IIH \u7684\u836f\u7269\u7684\u5e02\u573a\u6279\u51c6\u8981\u6c42\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002 \u65b0\u897f\u5170Medicines and Medical Devices Safety Authority (MEDSAFE) \u6279\u51c6\u4e86\u8be5\u8bd5\u9a8c\uff0c\u540c\u65f6 Invex \u83b7\u5f97\u4e86\u8be5\u56fd\u00a0Health and Disability Ethics Committee \u7684\u6279\u51c6\u3002 \u83b7\u5f97\u76d1\u7ba1\u90e8\u95e8\u7684\u6279\u51c6\u4e3a Invex \u5f00\u59cb\u62db\u52df\u60a3\u8005\u8fdb\u5165\u65b0\u897f\u5170\u8bd5\u9a8c\u81c2\u94fa\u5e73\u4e86\u9053\u8def\u3002 Invex \u6267\u884c\u8463\u4e8b\u517c\u9996\u5e2d\u79d1\u5b66\u5b98 Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u8be5\u516c\u53f8\u5df2\u6536\u5230\u65b0\u897f\u5170\u4e13\u4e1a\u4e34\u5e8a\u533b\u751f\u5173\u4e8e\u53c2\u4e0e IIH Evolve III \u671f\u8bd5\u9a8c\u7684\u5174\u8da3\u3002 \u4ed6\u8bf4\u4e34\u5e8a\u533b\u751f\u6b63\u5728\u5bfb\u627e\u65b0\u7684\u6709\u6548\u7597\u6cd5\u6765\u6cbb\u7597 IIH\uff0c\u56e0\u4e3a IIH \u7684\u53d1\u75c5\u7387\u4e0d\u65ad\u4e0a\u5347\uff0c\u540c\u65f6\u666e\u901a\u4eba\u7fa4\u7684\u80a5\u80d6\u7387\u4e5f\u5728\u4e0a\u5347\u3002 IIH\u00a0Evolve Invex \u672c\u5468\u65e9\u4e9b\u65f6\u5019\u5728\u5357\u6fb3\u5927\u5229\u4e9a\u7684 VisionSA \u62db\u52df\u4e86\u7b2c\u4e00\u4f4d\u968f\u673a\u60a3\u8005\u540e\uff0c\u4fbf\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u3002 \u5176\u4ed6\u8bd5\u9a8c\u7ad9\u70b9\u5df2\u5f00\u59cb\u5728\u6fb3\u5927\u5229\u4e9a\u548c\u82f1\u56fd\u79ef\u6781\u62db\u52df\uff0c\u5168\u7403\u603b\u5171\u5c06\u5f00\u8bbe40\u4e2a\u7ad9\u70b9\u200b\u200b\u3002 \u603b\u4e4b\uff0cIIH Evolve III \u671f\u8bd5\u9a8c\u5c06\u5bf9\u5927\u7ea6 240… Continue reading Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":19210,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-25T01:24:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:56:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-recruiting-IIH-patients-New-Zealand-NZ-clinical-trial-regulatory-approvals.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/\",\"name\":\"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-11-25T01:24:45+00:00\",\"dateModified\":\"2023-08-29T17:56:19+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c","description":"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c","og_description":"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/","og_site_name":"smallcapsCN","article_published_time":"2022-11-25T01:24:45+00:00","article_modified_time":"2023-08-29T17:56:19+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-recruiting-IIH-patients-New-Zealand-NZ-clinical-trial-regulatory-approvals.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/","name":"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-11-25T01:24:45+00:00","dateModified":"2023-08-29T17:56:19+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Invex Therapeutics (ASX: IXC) \u5df2\u83b7\u51c6\u5c06\u5176 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55\u5230\u65b0\u897f\u5170\uff0c\u5b83\u5c06\u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u8bc4\u4f30\u5176\u836f\u7269 Presendin\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u5c06\u5728\u83b7\u5f97\u76d1\u7ba1\u6279\u51c6\u540e\u5f00\u59cb\u5728\u65b0\u897f\u5170\u62db\u52df IIH \u60a3\u8005\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6135"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6135"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6135\/revisions"}],"predecessor-version":[{"id":16014,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6135\/revisions\/16014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/19210"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}